ObjectiveTo analyze the relationship among depression and anxiety and other possible factors in post-stroke patients.Methods510 hospitalized stroke patients from 1997 to 2004 were evaluated with the Scale of Elderly Cognitive Function (SECF), Self-Rating Depression Scale (SDS), Self-Rating Anxiety Scale (SAS), and Activities of Daily Living (ADL) in 7 days after admission and re-examined after two months.ResultsThe depression group exhibited the longer course of disease, a high ratio of hemiplegia in left side, lower ADL scores and higher SAS scores at time of admission. There were significant differences between depression and non-depression group. However, there was no significant difference between the depression and cognitive function. There were also significant differences between anxiety group and non-anxiety group. Patients with anxiety displayed symptoms of low ADL scores and higher SDS scores at time of admission, and ADL scores increased after treatment. Additionally, the course of disease was longer and reduction of anxiety level was lower. The levels of depression and anxiety significantly reduced in depression group and anxiety group when compared to the control group.ConclusionEarly rehabilitation can help to reduce depression level. Modest anxiety may help stroke patients to improve their ADL. There is close relationship between depression and anxiety.

ObjectiveTo compare the effect of psychological treatment only and psychological combined with fluoxetine treatment in reducing symptom of depression, anxiety and in improving of cognitive and daily living abilities for post-stroke depression patients.MethodsAll patients with post-stroke enrolled in hospital between 1996 and 2001 and were evaluated by using of the Self-rating Depression Scale (SDS), the Self-rating Anxiety Scale (SAS), Scale of Elderly Cognitive Function (SECF), and Ability of Daily Living (ADL). SDS score was equal or greater than 50 points (SDS≥50) selected as subjects for this study. A total of 115 patients were randomized divided into psychological with fluoxetine treatment group (Group A,54 patients) and psychological treatment group (Group B,61 patients). There is no significant difference between two groups in age, education, and left or right side of hemiplegics. Statistical analysis was performed by using Chi test and t test to compare the 2 groups at day 0 (baseline) and after 2 months.ResultsThe level of depression and anxiety reduced significantly in both Group A and Group B from baseline to end of treatment (P<0.001). Both groups had significant improvement in daily living ability (P<0.001).There was no significant improvement in cognitive ability (P>0.5). There was no significant differences on SDS, SAS, SECF, and ADL scores from baseline to end of treatment (P>0.5).Conclusions There were similar effect of psychological with fluoxetine treatment and of psychological treatment only on post-stroke depression.

Objective To analyze the injury mechanism and distribution of the motor vehicle engine shake shaft caused injuries (MVESSCI) in North Henan province. Methods A follow up was done on 520 patients with the motor vehicle engine shaft injuries treated in our hospital from January 1998 to May 2002. The epidemiological features were analyzed concerning gender, age, injury time and injury sites. Results There were 300 males and 220 females (age range of 9-53 years, mean 31 years) with ratio 1.36 ∶1 of male to female. The MVESSCI were dominated by Colles fractures and distal fractures of ulna and radius, accounting for 73.8% (384/520). The traffic accidents occurred most in May, June, September and October, which accounted for 85.0% (442/520). Conclusions (1) The vehicle engine shake shaft causes the injuries mainly at the distal part of the right forearm, mainly the Colles fracture and the distal fractures of ulna and radius. (2) The injury is mainly due to improper operation in busy farming seasons. (3) The countermeasures to reduce wounds and injuries are to pay much more attention to prevention, strengthen the safety awareness of individuals, improve the structures of motor vehicles and avoid improper manipulation of the vehicles by children.

Objective To discuss the therapeutic efficacy of budesonide and compound ipratropium bromide inhalated in treatment of infant bronchiolitis.Methods From January 2005 to February 2007,150 infants with bronchiolitis were randomly divided into treated group and control group.Both the two groups were treated with comprehensive treatment and antiviral therapy;control group were treated with budesonide suspemion and compound ipratropium bromide inhalated.Clinical efficacy of both two groups was evaluated.Results Cure rate of treatment group was 91%,cure rate of control group was 71%,the clinical therapeutic efficacy were compared between the two groups,the difference of which had statistical significance.Conclusion The result of experiment indicates that the therapeutic efficacy of budesonide and compound ipratropium bromide inhalated in treatment of infant bronchiolitis is better method.

Methylated DNA is considered as a new generation of tumor biomarker.It shows great value for evaluation of cancer risk,early detection and predicting prognosis.MS-HRM is a novel approach for quantitative assessment of methylation.It is based on the different base compositions after PCR amplification of bisulfite-modified DNA template,which give rise to different thermal properties of the PCR products originating from methylated or unmethylated target template.This article describs the advantages of this method and its role in the detection of cancer and inherit disease.The prospective application in the molecular diagnosis is also suggested.

During the past 30 years, Alzheimer's disease (AD) drug R&D aiming at a variety of potential targets has undergone tremendous setback although a large amount of resources have been invested by pharmaceutical companies, governments, academic institutions and venture capitals globally. There is no doubt that uneasy early diagnosis, unsatisfying therapeutic strategies and genetic polymorphism of AD patients bringing variety of responses to the drugs contribute to the failure of AD drug therapy, but the most important reason might be that people have insufficient understanding of the very complex diseases including AD. Continuing to make efforts in the previous way to find AD drugs might not be a good way. Development of systems biomedicine opens an avenue to understand the disease networks and pursue multi-target drugs R&D based on systems pharmacology theory; neural stem cell transplantation, and neurogenesis affected by small molecules might bring new hope for AD therapy; discovery of new biomarkers of AD will help the study of the pathogenesis and diagnosis of the disease and finally the discovery of new types of AD drugs.
Alzheimer Disease ; drug therapy ; Biomedical Research ; trends ; Humans

Humans ; Purpura, Thrombocytopenic, Idiopathic

Tuberculosis a disease with the highest death rate by single pathogenic infection can cause serious harm to human health .MicroRNA ( miRNA ) is a classical single-stranded, short RNA molecules ( about 21 to 25 nucleotides ) that plays an important role in cell proliferation , differentiation , senescence and apoptosis by inhibiting the post-transcriptional gene expression or promoting degradation of target gene mRNA . Recent studies have shown that miRNA involved in the regulation of apoptosis , expression of pro-inflammatory cytokines , inflammation-related signaling pathways in tuberculosis infection . Meanwhile, miRNA may be a new biomarker for tuberculosis diagnosis.

During the past 30 years, Alzheimer's disease (AD) drug R&D aiming at a variety of potential targets has undergone tremendous setback although a large amount of resources have been invested by pharmaceutical companies, governments, academic institutions and venture capitals globally. There is no doubt that uneasy early diagnosis, unsatisfying therapeutic strategies and genetic polymorphism of AD patients bringing variety of responses to the drugs contribute to the failure of AD drug therapy, but the most important reason might be that people have insufficient understanding of the very complex diseases including AD. Continuing to make efforts in the previous way to find AD drugs might not be a good way. Development of systems biomedicine opens an avenue to understand the disease networks and pursue multi-target drugs R&D based on systems pharmacology theory; neural stem cell transplantation, and neurogenesis affected by small molecules might bring new hope for AD therapy; discovery of new biomarkers of AD will help the study of the pathogenesis and diagnosis of the disease and finally the discovery of new types of AD drugs.